REGENERON PHARMACEUTICALS, INC.

REGN 10-K · Q4 2025
API behind this page

REGN Q4 2025 request

Playground key active
Request URL /api/financials?ticker=REGN&year=2025&quarter=4
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q4 2025 Q4 2024 YoY
Revenue 3,884.3 3,789.2 +2.5%
Show Product Lines breakouts
Collaboration revenue 1,970.9 1,606.9 +22.7%
ELYEA HD And EYLEA · US 1,083.2 1,495 -27.5%
ELYEA HD · US 506.3 304.6 +66.2%
Evkeeza · US 47.3 38.1 +24.1%
EYLEA · US 576.9 1,190.4 -51.5%
Libtayo 425.4 366.9 +15.9%
Libtayo · Non Us 140.1 115.7 +21.1%
Libtayo · US 285.3 251.2 +13.6%
Praluent · US 72.2 62.7 +15.2%
Product 1,674.8 2,002.9 -16.4%
Product And Service Other 238.6 179.4 +33.0%
Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses · Non Us -1.1 -13.3 +91.7%
Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses · Sanofi Collaboration Agreement, Antibody -12.6 -11.3 -11.5%
Regeneron's share of profits · Non Us 270.1 348.8 -22.6%
Regeneron's share of profits · Sanofi Collaboration Agreement, Antibody 1,485.9 1,042.9 +42.5%
Reimbursement for manufacturing of commercial supplies · Non Us 48.6 28.3 +71.7%
Reimbursement for manufacturing of commercial supplies · Sanofi Collaboration Agreement, Antibody 154.3 169.7 -9.1%
Reimbursement of commercialization-related expenses · Sanofi Collaboration Agreement, Antibody 193.5 196.1 -1.3%
Research & Development 1,626.1 1,412.1 +15.2%
Show Business Segments breakouts
Reportable Segment 1,626.1 1,412.1 +15.2%
Reportable Segment · Clinical manufacturing costs 362.4 354.6 +2.2%
Reportable Segment · Direct research and development expenses 461.4 430.3 +7.2%
Reportable Segment · Indirect research and development expenses 65.8 66.1 -0.5%
Reportable Segment · Indirect research and development expenses 156.2 180 -13.2%
Reportable Segment · Indirect research and development expenses 461.3 432.5 +6.7%
Reportable Segment · Indirect research and development expenses 683.3 678.6 +0.7%
Acquired In Process Research And Development 18.7 13.8 +35.5%
Selling, General & Administrative 775 792.2 -2.2%
Cost of Revenue (Q) — — —
Show Product Lines breakouts
Cost of collaboration and contract manufacturing 265.9 238.6 +11.4%
Product 318.7 326.8 -2.5%
Other Operating Income Expense Net 0 15.5 -100.0%
Total Costs & Expenses 3,004.4 2,799 +7.3%
Operating Income 879.9 990.2 -11.1%
Other Non-Operating Income (Expense) 176 -21.6 +914.8%
Interest Expense -12.2 -10.5 -16.2%
Non-Operating Income (Expense) 163.8 -32.1 +610.3%
Income Before Taxes 1,043.7 958.1 +8.9%
Income Tax Expense (Benefit) 199.1 40.4 +392.8%
Net Income 844.6 917.7 -8.0%
EPS (Basic) 8.24 8.54 -3.5%
EPS (Diluted) 7.87 8.11 -3.0%
Wtd Avg Shares (Basic) -0.5 -0.1 -400.0%
Wtd Avg Shares (Diluted) -0.3 -0.5 +40.0%
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax 7.1 -66 +110.8%
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent 1.4 -2.1 +166.7%
Comprehensive Income 853.1 849.6 +0.4%

Balance Sheet

Balance Sheet
Metric Q4 2025 Q4 2024 YoY
Current Assets
Cash & Cash Equivalents 3,118.1 2,488.2 +25.3%
Marketable Securities (Current) 5,487.1 6,524.3 -15.9%
Accounts Receivable 5,741.1 6,211.9 -7.6%
Show Accounts Notes Loans And Financing Receivable By Receivable Type breakouts
Trade Accounts Receivable 3.46 4.28 -19.2%
Show Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project breakouts
Bayer 287.6 349.9 -17.8%
Sanofi Collaboration Agreement, Antibody 1,610.6 1,216.2 +32.4%
Inventory 3,200.8 3,087.3 +3.7%
Prepaid Expenses & Other Current Assets 474.8 349.2 +36.0%
Total Current Assets 18,021.9 18,660.9 -3.4%
Non-Current Assets
Marketable Securities (Non-Current) 10,260.6 8,900.1 +15.3%
Deferred Tax Assets 4,077.2 3,314.1 +23.0%
Other Non-Current Assets 1,821.2 1,136 +60.3%
Total Assets 40,558.7 37,759.4 +7.4%
Operating Lease Right-of-Use Assets 245.8 217.4 +13.1%
Intangible Assets (Q) — — —
Show Finite Lived Intangible Assets By Major Class breakouts
Acquired product rights - Libtayo 1,203.4 1,093.4 +10.1%
Other Intangible Assets 1.2 2.4 -50.0%
Other Assets
Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization 5,120.4 4,599.7 +11.3%
Show Geography breakouts
Non Us 788 715.9 +10.1%
US 4.33 3.88 +11.5%
Intangible Assets Net Excluding Goodwill 1,257.4 1,148.6 +9.5%
Current Liabilities
Accounts Payable 939 789.5 +18.9%
Accrued Liabilities And Other Liabilities 2,876.4 2,527.1 +13.8%
Deferred Revenue (Current) 553 627.7 -11.9%
Total Current Liabilities 4,368.4 3,944.3 +10.8%
Non-Current Liabilities
Long-Term Debt 1,985.9 1,984.4 +0.1%
Finance Lease Liability Noncurrent 720 720 0.0%
Contract With Customer Liability Noncurrent 208.7 185.7 +12.4%
Other Non-Current Liabilities 2,018.8 1,571.4 +28.5%
Total Liabilities 9,301.8 8,405.8 +10.7%
Long-Term Debt (Q) — — —
Show Debt Instrument breakouts
1.750% Senior Notes due September 2030 · Senior Notes 1,244.5 1,243.3 +0.1%
2.800% Senior Notes due September 2050 · Senior Notes 741.4 741.1 0.0%
Show Long-Term Debt Type breakouts
Senior Notes 1,985.9 1,984.4 +0.1%
Operating Lease Liabilities 229 204.1 +12.2%
Stockholders' Equity
Common Stock (Q) — — —
Show Statement Class Of Stock breakouts
Common Stock 0.1 0.1 0.0%
Additional Paid-In Capital 13,995 12,855.9 +8.9%
Retained Earnings 35,797.1 31,672.9 +13.0%
Accumulated Other Comprehensive Income 77.5 -7.9 +1081.0%
Treasury Stock Common Value -18,612.8 -15,167.4 -22.7%
Total Stockholders' Equity 31,256.9 29,353.6 +6.5%
Show Equity Components breakouts
Accumulated Other Comprehensive Income 77.5 -7.9 +1081.0%
Additional Paid In Capital 13,995 12,855.9 +8.9%
Common Stock 0.1 0.1 0.0%
Retained Earnings 35,797.1 31,672.9 +13.0%
Treasury Stock Common -18,612.8 -15,167.4 -22.7%
Total Liabilities & Equity 40,558.7 37,759.4 +7.4%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q4 2025 YTD Q4 2024 YoY
Operating Activities
Depreciation & Amortization 145 126.4 +14.7%
Stock-Based Compensation 249.3 304.4 -18.1%
Marketable And Other Securities Gain Loss 21.5 212.9 -89.9%
Other Non-Cash Items 136.9 68 +101.3%
Increase Decrease In Deferred Income Taxes -232.5 -280.2 +17.0%
Change in Accounts Receivable -51.2 -117.8 +56.5%
Change in Inventory 2.1 -117.7 +101.8%
Change in Prepaid & Other Assets 82.8 -55.3 +249.7%
Change in Deferred Revenue -3.1 -21.2 +85.4%
Increase Decrease In Accounts Payable And Accrued Liabilities -24.7 225.6 -110.9%
Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities 326.1 345.1 -5.5%
Net Cash from Operations 1,170.7 1,262.8 -7.3%
Investing Activities
Payments To Acquire Marketable Securities -2,043.7 -1,952.9 -4.6%
Proceeds From Sale And Maturity Of Marketable Securities 2,555 2,582 -1.0%
Payments To Acquire Productive Assets -248.7 -199.6 -24.6%
Payments To Acquire Intangible Assets1 -42 -67.4 +37.7%
Payments To Acquire Businesses Net Of Cash Acquired -0.3 -11.5 +97.4%
Net Cash from Investing 220.3 350.6 -37.2%
Financing Activities
Proceeds From Issuance Of Common Stock 503.5 90.9 +453.9%
Tax Withholding for Share Compensation -519.2 -253.4 -104.9%
Share Repurchases -671.7 -973 +31.0%
Proceeds From Payments For Other Financing Activities 0 0 —
Net Cash from Financing -780.1 -1,135.5 +31.3%
Supplemental
Unpaid Capital Expenditures 1.9 57.6 -96.7%
Other Cash Flow
Net Change in Cash 610.6 477.2 +28.0%
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 3,123.7 2,489 +25.5%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key